Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Operating and Financial Results

Dova Pharmaceuticals (NASDAQ:DOVA) a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, today reported its operating and financial results for the fourth quarter and full-year ended December 31, 2017.

As quoted in the press release:

Alex Sapir, President and Chief Executive Officer of Dova, commented, “The highlight of the fourth quarter was acceptance of avatrombopag with Priority Review by the FDA. This designation represents a validation of the need for a novel therapy for the more than 70,000 CLD patients with severe thrombocytopenia in the United States.  Dova remains focused on gaining FDA approval for avatrombopag and developing the commercial infrastructure to support the potential launch of the product.”

Click here to read the full press release.